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Introduction: The benefit of cardiac resynchronization therapy (CRT) in heart failure 
(HF) patients with reduced left ventricular ejection fraction (LVEF) have been ob-
served in the first year. However, there are few data on long- term follow- up and the 
effect of changes of LVEF on mortality. This study aimed to assess the LV remodeling 
after CRT implantation and the probable effect of changes in LVEF with repeated 
measures on mortality over time in a real- world registry.
Methods: Among our cohort of 328 consecutive CRT patients, mixed model effect 
analysis have been made to describe the temporal evolution of LVEF and LVESV 
changes over time up with several explanatory variables. Besides, the effect of LVEF 
along time on the probability of mortality was evaluated using joint modeling for 
longitudinal and survival data.
Results: The study population included 328 patients (253 men; 70.2 ± 9.5 years) in 4.2 
(2.9) years follow- up. There was an increase in LVEF of 11% and a reduction in LVESV of 
42 mL during the first year. These changes are more important during the first year, but 
slight changes remain during the follow- up. The largest reduction in LVESV occurred 
in patients with left bundle branch block (LBBB) and the smallest reduction in patients 
with NYHA IV. The smallest increase in LVEF was an ischemic etiology, longer QRS, and 
LV electrode in a nonlateral vein. Besides, the results showed that the LVEF profiles 
taken during follow- up after CRT were associated with changes in the risk of death.
Conclusion: Reverse remodeling of the left ventricle is observed especially during 
the first year, but it seems to be maintained later after CRT implantation in a con-
temporary cohort of patients. Longitudinal measurements could give us additional 
information at predicting the individual mortality risk after adjusting by age and sex 
compared to a single LVEF measurement after CRT.
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1  | INTRODUC TION
Cardiac remodeling occurs due to abnormal neurohormonal regu-
lation in heart failure (HF) patients.1,2 The principal feature of re-
modeling is left ventricular (LV) dilatation and deterioration of LV 
function. Major clinical trials have demonstrated the benefit of car-
diac resynchronization therapy (CRT) in HF patients with reduced 
LVEF.3- 9 It is well established for patients with left ventricular sys-
tolic dysfunction and ventricular conduction delay under optimal 
medical therapy. CRT has been shown to improve functional class, 
reduce hospitalization and mortality among patients with symptom-
atic HF, as well as LV reverse remodeling. The concept of cardiac 
reverse remodeling was developed to explain the reduction of LV 
volumes and improvements in LV function observed with the use of 
medical therapies for HF and CRT.10 Currently, the reduction of left 
ventricular end- systolic volume (LVESV) ≥15% and/or the increase 
in the absolute value of left ventricular ejection fraction (LVEF) 
≥5% at 6- 12 months have been identified as predictors of clinical 
prognosis and response to CRT.10- 13 Evidence suggests that the im-
proved outcomes observed with CRT are associated with reverse 
remodeling.14- 17
Up to date, randomized clinical trials of CRT have documented 
increases in LVEF and/or reduction in LV volumes in the first year 
after CRT implantation. However, there are scarce data on the mid- 
term and long- term benefit of this therapy and the sustained effect 
of ventricular remodeling over a prolonged follow- up period. In ad-
dition, it remains unknown the effect of LVEF on mortality over time. 
Here, we evaluate the long- term cardiac reverse remodeling after 
CRT in patients with repeated echocardiographic measurements in 
a contemporary patient registry and how changes in LVEF over time, 
with several measurements per patient, may better predict the indi-
vidual risk of mortality.
2  | METHODS
This retrospective follow- up study includes 328 consecutive pa-
tients with cardiac resynchronization therapy— defibrillator (CRT- 
D) or pacemaker (CRT- P) under standard clinical indications in a 
single tertiary cardiac institution between January 2005 and April 
2015. All the patients demonstrated HF symptoms (New York Heart 
Association— NYHA— functional class II, III or ambulatory IV symp-
toms), with ischemic or nonischemic cardiomyopathy, decreased 
LVEF (≤35%), and prolonged QRS duration (≥120 ms) at the time of 
implantation. They received pharmacological treatment for HF up- 
titrated to the maximal tolerated doses according to the European 
Society of Cardiology guidelines for the management of HF at the 
discretion of the treating cardiologist.
We registered the baseline characteristics of all of the pa-
tients. Electrocardiographic features included QRS width 
and morphology. Echocardiographic parameters included LV 
end- diastolic (LVEDV) and end- systolic volume (LVESV), LVEF, 
left atrial diameter (LAD), and mitral regurgitation. For the 
quantification of the severity of mitral regurgitation, the ratio 
between the maximum regurgitant jet obtained from the flow 
image by color doppler and the area of the left atrium was used. 
In cases of eccentric mitral regurgitation, the contracted vein 
was used for quantification. The patients were followed up in 
the Heart Failure Clinic every 3 or 6 months and in the CRT- 
Device Clinic every 6 months. Electrocardiogram and echo-
cardiogram were also performed at the 6- month and 2- year 
follow- ups and according to the discretion of the HF cardiol-
ogist. Treating cardiologists followed a specified protocol to 
achieve OMT. Patients with decreases in LVESV exceeding 15% 
and/or improvements in LVEF of more than 5% were considered 
to be echocardiographic responders. Patients with improve-
ments in one category in NYHA functional class were considered 
to be clinical responders.
This study was conducted in accordance with the Principles of 
the Declaration of Helsinki. The clinical study (2017/171) was ini-
tially approved in 2017 by the Clinical Research Ethics Committee 
(CEIC) of Galicia.
2.1 | Statistical analysis
Qualitative variables are expressed as frequency and percentages. 
Quantitative variables are presented as mean (SD) or as a median 
(interquartile range) as appropriate. The chi- square test X2 or U of 
Mann- Whitney was used to compare qualitative variables. P ≤ .05 
was considered statistical significance.
Mixed effects models have been fitted to describe the relation-
ship between echocardiographic changes (LVEF and LVESV) in the 
follow- up as a function of several explanatory covariates (age, sex, 
etiology, NYHA class, rhythm in the time of implantation, morphol-
ogy, and duration of the baseline QRS, location of the electrode in 
the coronary sinus). These models contain both fixed and random ef-
fects, possibility of correlated data, and variability heterogeneous.18 
They are particularly useful in settings where repeated measure-
ments are made on the same units (longitudinal study). Besides, this 
model allows to deal with missing values.
Joint modeling for longitudinal and survival data was used to 
model the relationship between LVEF profiles over time and mortal-
ity. These models allow dynamic predictions of the risk of mortality 
of individuals updating and improving with every new longitudinal 
observation.19 All statistical analyses were performed with the soft-
ware R (CRAN- R).20
3  | RESULTS
3.1 | Patient characteristics
The study population included 328 patients (253 men and 75 women; 
mean age: 70.2 (9.5) years) who were consecutively implanted with 
a CRT device at our institution. The mean follow- up duration was 
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4.2 (2.9) years. Of the 328 patients, only 122 (37.2%) were on triple 
neurohormonal therapy at the time of implantation. The baseline 
characteristics are listed in Table 1.
3.2 | Baseline echocardiographic characteristics
The mean baseline LVEF was 28%. In our sample more than half 
of the patients had severe mitral regurgitation at the time of 
the CRT implant due to severe dilatation of the LV (182, 55.5%) 
and 13 (4.0%) did not present mitral regurgitation prior to CRT. 
LVESV and LVEDV were 156 (55) mL and 215 (64) mL, respec-
tively (Table 1).
3.3 | Mortality at follow- up
The probability of survival at 1 year was 89.2%, at 5 years was 61.3% 
and at 10 years was 33.4%. Six patients were transplanted at 3 years 
after undergoing the CRT. During the first year of follow- up, 34 
(10.4%) patients died; 55.9% were cardiovascular mortality, mostly 
due to heart failure (73.7%). The causes of mortality were: 44.0% 
(55) cardiovascular mortality (74.5% HF, 21.9% arrhythmias, 3.6% 
coronary syndromes), 30.4% (38) no cardiovascular mortality (60.5% 
infections, 21.1% neoplasia, 18.4% bleeding events), and 25.6% (32) 
other and unknown.
3.4 | Echocardiographic characteristics at follow- up
The echocardiogram was performed during the first year and then 
every 2 years, at the request of the responsible clinician or dur-
ing the patient's clinical deterioration. At follow- up, a maximum of 
four measurements of the echocardiographic parameters were per-
formed in patients with CRT. The first postimplant echocardiogram 
was obtained in 327 patients (one patient died during implant admis-
sion), the measurements of two echocardiograms were obtained in 
181 patients, three measurements in 51 patients, and four measure-
ments in 10 patients.
In the first year, LVEF increased by 11% and LVESV decreased 
by 42 mL. We have also identified that 68 patients (20.7%) pre-
sented normalization of the function and structure of the LV, as-
sociated with a better clinical prognosis. The changes in LVEF and 
LVESV profiles are observed especially during the first year, but 
improvements in LVEF and LVESV are not only maintained, but 
slightly increase in a longer follow- up (Figure 1). This may be influ-
enced because patients who die are excluded, 10.4% died during 
the first year and 38.2% at the end of follow- up. Of them, 12 (3.7%) 
patients had sudden death.
Changes are observed during the first year in both sexes, but 
more marked in women than in men. It is also observed in patients 
with nonischemic cardiomyopathy. However, the response to CRT in 
patients with ischemic HF is unchanged in the long term. Patients in 
NYHA III class, and with LV lead located in posterior and lateral veins 
have better reverse remodeling of LV (Figures S1- S5).
TA B L E  1   Baseline characteristics
Characteristics n = 328
Sex: female, n (%) 75 (22.9)
Age (y) 70.2 (9.5)
Ischemic cardiomyopathy, n (%) 119 (36.3)
CRT- D, n (%) 211 (64.3)




Diabetes Mellitus, n (%) 77 (23.5)
Atrial fibrillation, n (%) 123 (37.5)
AV node ablation, n (%) 23 (7.0)
Creatinine (mg/dl) 1.3 (0.6)
Hemoglobine level (g/dl) 13 (2.0)




QRS duration (ms) 162 (26.0)






BB, n (%) 271 (82.6)
ACEI/ARB- II, n (%) 283 (86.3)
MRA, n (%) 154 (47.0)
Echocardiographic parameters
LVESV (mL) 215 (64)
LVEDV (mL) 156 (55)






Left atrial volume (mL) 72 (15)
Abbreviations: ACEI, angiotensin- converting enzyme inhibitors; 
ARB- II, angiotensin II receptor blockers; AV, atrio ventricular; BB, 
beta- blockers; CRT- D, cardiac resynchronization therapy - defibrillator; 
IVCD, intraventricular conduction delay; LBBB, left bundle branch 
block; LVEDV, left ventricular end- diastolic volume; LVEF, left 
ventricular ejection fraction; LVESV, left ventricular end- systolic 
volume; MRA, mineralocorticoid receptor antagonist; NYHA, New 
York Heart Association; RBBB, right bundle branch block; RVP, right 
ventricular pacing.
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The increases in LVEF greater than 5% and reductions in LVESV 
greater than 15% were associated with a reduction in mortality risk 
(Figure 2). Table 2 shows the variables associated with changes in LVEF 
and LVESV during follow- up. The largest reduction in LVESD occurred 
in patients with LBBB (left bundle branch block), and the smallest re-
duction in patients with advanced functional class (NYHA IV class). 
The smallest increase in LVEF was observed in patients with ischemic 
etiology, longer QRS and location of the VI lead in a nonlateral vein of 
coronary sinus. Figure 3 shows the changes of the LVEF and LVESV 
along time after adjusting by potential confounding variables.
3.5 | Joint modeling analysis
A survival prediction model has been carried out over time adjusted 
on age, sex, and changes of LVEF over time using the joint modeling 
methodology. Table 3 shows the relative risks with their correspond-
ing confidence intervals. The analysis showed that the increase in 
LVEF after CRT was associated with higher survival rates. Male sex 
and older age were associated with a worse prognosis.
4  | DISCUSSION
This study provided a real- world registry to evaluate the long- term 
effect of CRT on LV reverse remodeling assessed by longitudinal LV 
structural and functional measurements over time in HF patients. 
CRT promotes a greater degree of reverse remodeling during the 
first year postimplant that is slightly enhanced in the long- term 
follow- up, especially in patients of female and nonischemic etiol-
ogy. Moreover, variations of LV remodeling over time, analyzed 
using mixed models, have allowed us to improve the identification 
of reverse remodeling predictors. The main factors independent for 
predicting the improvement of LVEF have been the nonischemic eti-
ology, higher duration of baseline QRS, and location of the LV lead 
in the lateral vein of the coronary sinus. The main factor for the pre-
diction of the reduction of LVESV has been the presence of LBBB. 
Finally, the longitudinal changes in LVEF at follow- up improves the 
prediction of the mortality risk after adjusting for age and sex, by 
using the joint modeling analysis. To our knowledge, this is the first 
time to describe the effect of CRT on LV remodeling in a real- world 
registry. Our results have several implications, on the one hand, we 
describe the temporal evolution of cardiac morphology and function 
after CRT in a contemporary cohort of patients at follow- up. On the 
other hand, we showed that the effect of CRT is observed in the 
long term, but especially in the first year. So it would be essential to 
optimize pharmacological treatment during this period in order to 
obtain the greatest benefit early, especially in patients with a worse 
response profile to CRT.
Reverse remodeling is one of the hallmark findings of CRT stud-
ies in mild and advanced HF patients. So far, there are few data on 
the mid- and long- term of the ventricular remodeling.10- 17 It was well 
F I G U R E  1   Evolution of changes in 
left ventricular ejection fraction (LVEF) 
and left ventricular end- systolic volume 
(LVESV) during follow- up
F I G U R E  2   Effects of LVEF and LVESV changes on mortality risk. Interpretation: Taking the value of 5 on the X axis as the reference value 
for the change in LVEF, the logarithm of the relative risk of mortality for the change in LVEF is shown. For example, a 30- point improvement 
in LVEF decreases the log RR by −1, which means that the relative risk of death is 2.72 times lower than a 5- point improvement in LVEF. For 
the LVESV value, the reference value is 15. For LVESV reductions of 30, they will present a reduction in the relative risk of mortality 2.72 
times greater than changes in LVESV of 15 (the number e, used as the base for a logarithm, is approximately equal to 2.72)
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established the effect in the first 6- 12 months after CRT. This was 
assessed in randomized clinical trials, that showed that CRT added 
to standard pharmacological therapy for HF, causes a sustained im-
provement in LV geometry and function in the first months after 
CRT. In patients with HF, pharmacological agents and CRT reduce 
the mortality and morbidity, also improve the geometry and function 
of the LV. Reverse ventricular remodeling was first evaluated in the 
PATH- CHF study at 12 months later to the implant and from there 
multiple studies have assessed the echocardiographic response to 
CRT and determined what characteristics could influence the re-
verse remodeling.21
Nowadays, the assessment of left ventricular remodeling after 
CRT is determined with the reduction of LVESV ≥ 15% or the in-
crease in the absolute value of LVEF ≥ 5% at 6- 12 months. It is well 
established that the LV remodeling induced by CRT has been related 
to the improvement of the quality of life, functional class, reduction 
of mortality, and HF hospitalizations.22,23 Most clinical trials have 
evaluated the LV remodeling during the 6- 12 months after CRT im-
plantation. But so far, there is little evidence of the effect of CRT on 
LV remodeling during longer term follow- up in real- world. This study 
describes for the first time in a real- world contemporary registry the 
long- term effect of CRT on LV remodeling.
In a sub- analysis of CARE HF trial, CRT induced sustained LV re-
verse remodeling in the long- term follow- up with the most marked 
effects occurring within the first 3- 9 months. This effect may con-
tribute to an improvement in morbidity and mortality. These bene-
ficial effects were observed even in ischaemic patients and patients 
with very severe cardiac dysfunction.24 MIRACLE study investigated 
serial changes in LV size and function by using longitudinal data anal-
ysis in a consecutive cohort of patients with long- term follow- up. 
These changes were more pronounced at 6 months and remained 
during the long- term, but they became much less pronounced. 
Besides, patients with an uneventful survival demonstrated a greater 
decrease in the LVESV compared with patients with adverse events. 
Factors associated with less reverse remodeling were ischemic etiol-
ogy, male sex, and QRS duration <140 ms.25 Similarly, the reverse LV 
TA B L E  2   Multivariable analysis (mixed model effects) to predict 
the change in LVEF (P < .0001 with degrees of freedom (df) 2.42) 







Male −2.096 1.64 .2019
Age (y) 0.013 0.07 .8495
Ischemic cardiomyopathy −3.09 1.398 .0275
NYHA class
III −2.137 1.529 .1628
IV −0.826 3.018 .7843
AF −1.095 1.365 .4228
LBBB 1.367 1.341 .3084
QRS duration −0.068 0.025 .0069
Coronary sinus vein
Lateral 3.458 1.715 .0443
Posterior 3.514 1.969 .0648
Intercept 22.907 6.328 .0003
Mixed model LVESV
Male 6.119 4.766 .1999
Age −0.064 0.193 .7409
Ischemic cardiomyopathy 7.005 4.053 .0848
NYHA
III 6.839 4.016 .0894
IV 31.88 10.463 .0025
AF 2.397 3.833 .5321
LBBB −7.923 3.809 .0382
QRS duration 0.075 0.076 .3222
Coronary sinus vein
Lateral −6.481 5.549 .2435
Posterior −10.419 6.052 .086
Intercept −37.678 18.029 .0373
Abbreviations: AF, atrial fibrillation; LBBB, left bundle branch block; 
NYHA, New York Heart Association.
F I G U R E  3   Evolution of the change 
of LVEF (A) and LVESV (B) adjusted for 
confounding variables over time (LVEF: 
P < .001 with 2.42 degrees of freedom; 
LVESV: P < .001 with 2.45 degrees of 
freedom)
TA B L E  3   Multivariable Analysis (Joint model) for mortality in HF 
patients after TRC during long- term follow- up
Coefficient (SE) HR (CI 95%)
Age (y) 0.05 (0.01) 1.05 (1.03- 1.07)
Male 0.57 (0.23) 1.57 (1.12- 2.77)
LVEF, % (∆) −0.03 (0.01) 0.97 (0.95- 0.98)
Abbreviations: CI, confidence interval; HR, hazard ratio; LVEF, left 
ventricular ejection fraction; SE, standard error; ∆, changes.
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remodeling of CRT in a sub- analysis of REVERSE trial was sustained 
over 5 years. The functional and LV remodeling improvements were 
maximal after 2 years and were accompanied by very low mortality 
and HF hospitalization, although the largest change in LV volumes 
was noted in the first year with further remodeling.26
We show for the first time in a registry of real- world patients the 
variation of echocardiographic measures over time and factors in-
volved in their variations long- term follow- up. One of the main findings 
is the maintaining of a favorable evolutionary profile over years after 
the first year when the most LV reverse remodeling was observed. We 
observed better ventricular remodeling in women, nonischemic etiol-
ogy, LBBB morphology, and LV lead in a lateral vein of the coronary 
sinus similar with randomized CRT trials. We have also observed that 
the evolutionary patterns of LVEF and LVESV have been very hetero-
geneous, due to both the individual characteristics of each patient, the 
location and type of lead in the coronary sinus and intercurrent pro-
cesses that they could appear in the natural history of HF. These could 
be explained because more than a quarter of patients will not present 
an adequate echocardiographic response, despite good patient selec-
tion.27 However, Burns et al showed that the time course of improve-
ments in LV size and function after the initiation of CRT can evidence 
a slower and delayed positive CRT response after 6- 12 months of 
therapy.28 These findings could also explain the maintaining of the 
long- term ventricular remodeling that we have observed in our work. 
Furthermore, after CRT implantation there could be a hemodynamic 
improvement and thus a greater prescription of well evidence- based 
treatments. Then, the synergistic effect of CRT and pharmacologi-
cal treatment could improve structural remodeling during follow- up. 
Besides, we have established, through dynamic prediction models, the 
individualized probability of patient survival through changes in LVEF 
with repeat measurements over time. This provides more information 
on mortality risk than a single determination of LVEF after implanta-
tion of CRT, after adjusting by age and sex. In our sample, the survival 
individually prediction through the models of dynamic prediction with 
repeated measurements of LVEF in follow- up, could help to identify 
patients at higher risk who require closer monitoring, optimization of 
drug treatment and / or management of comorbidities. These models 
are probably the future of personalized medicine and could allow to 
establish computational algorithms of response to CRT that allow pre-
diction what is the individual risk of both mortality and cardiovascular 
events at a specific time during follow- up of each patient.
5  | LIMITATIONS
The retrospective nature of this analysis conducted at a single center 
is a potential weakness. As a consequence, the patient sample size 
was limited. This is an observational registry with their inherent limi-
tations (eg selection bias, unmeasured bias), and thus associations 
may be confounded by unmeasured variables. Several unmeasured 
confounders or details about physician or patient decision- making 
might not be available in our collection data protocol and could ac-
count for some of the reported findings. Also, there may have been 
appropriate contraindications to adjunctive pharmacotherapy that 
were nor collected. In addition, during the echocardiographic follow-
 up, patients who died are excluded from the analysis and this can be 
a positive bias because only surviving patients were included in the 
analysis. Finally, long- term outcomes could be modified by many cir-
cumstances that might not be available or controlled in the follow- up 
protocol of our center. As such, the results presented in this analysis 
should be considered hypothesis- generating and deserve confirma-
tion in other registries and clinical trials.
6  | CONCLUSIONS
Reverse remodeling of the left ventricle is observed especially in 
the first year after CRT implantation and this effect is maintained a 
long time in a contemporary cohort of patients. Longitudinal LVEF 
measurements throughout the follow- up could predict better the in-
dividual mortality risk adjusting for potential confounding variables.
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